Clinical Trial

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2023 (before its estimated November 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-07-17.
Status change: Not Yet Recruiting → Recruiting 2023-11-15
Trial Details
NCT Number NCT05960955
Lead Sponsor Akeso
Conditions Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 90 participants
Start Date 2023-11-13
Primary Completion 2024-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-18